Lisa A. Jackson, MD, MPH, is an internist and infectious disease epidemiologist who has conducted clinical and epidemiologic studies of vaccine safety and efficacy since 1991.
Dr. Jackson is the principal investigator (PI) of KPWHRI’s Vaccine and Treatment Evaluation Unit — one of 10 network sites that the National Institutes of Health (NIH) sponsors. In this role, she leads the phase 1 clinical trial of the COVID-19 vaccine co-developed by Moderna and NIH. Launched in March 2020, this trial was the first in the world to begin testing a COVID-19 vaccine. She is also leading the phase 3 clinical trials of the COVID-19 vaccines developed by Moderna and NIH and by Janssen Pharmaceutical Companies, part of Johnson & Johnson, at KPWHRI.
Additionally, Dr. Jackson serves as KPWHRI’s principal investigator in the Vaccine Safety Datalink Project (VSDP). Sponsored by the Centers for Disease Control and Prevention (CDC), VSDP conducts ongoing research on the safety of licensed vaccines in routine use.
Dr. Jackson has written more than 200 peer-reviewed publications and 14 book chapters. She is a past member of the Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee and the National Vaccine Program Office’s National Vaccine Advisory Committee.
After receiving her medical degree from the University of Virginia School of Medicine, in Charlottesville, Dr. Jackson earned her Master of Public Health (MPH) degree at the University of Washington (UW) School of Public Health. She completed her internal medicine residency training at the UW School of Medicine and served as an epidemic intelligence officer and preventive medicine resident at the CDC.
Vaccine safety; COVID-19 vaccine safety and effectiveness; influenza vaccine effectiveness in the elderly; methodologic issues in vaccine effectiveness evaluations; pneumococcal polysaccharide vaccine effectiveness; pneumococcal conjugate vaccine immunogenicity in the elderly; epidemiology of E. coli bacteremia; epidemiology of community-acquired pneumonia
Chung JR, Kim SS, Flannery B, Smith ME, Dunnigan K, Raiyani C, Murthy K, Gaglani M, Jackson ML, Jackson LA, Bear T, Moehling Geffel K, Nowalk MP, Zimmerman RK, Martin ET, Lamerato L, McLean HQ, King JP, Belongia EA, Thompson MG, Patel M. Vaccine-associated attenuation of subjective severity among outpatients with influenza. Vaccine. 2022 Jul 30;40(32):4322-4327. doi: 10.1016/j.vaccine.2022.06.019. Epub 2022 Jun 14. PubMed
Zerbo O, Modaressi S, Goddard K, Lewis E, Fireman B, Daley MF, Irving SA, Jackson LA, Donahue JG, Qian L, Getahun D, DeStefano F, McNeil MM, Klein NP. Safety of measles and pertussis-containing vaccines in children with autism spectrum disorders. Vaccine. 2022 Apr 20;40(18):2568-2573. doi: 10.1016/j.vaccine.2022.03.031. Epub 2022 Mar 18. PubMed
Chung JR, Kim SS, Belongia EA, McLean HQ, King JP, Nowalk MP, Zimmerman RK, Moehling Geffel K, Martin ET, Monto AS, Lamerato LE, Gaglani M, Hoffman E, Volz M, Jackson ML, Jackson LA, Patel MM, Flannery B. Vaccine effectiveness against COVID-19 among symptomatic persons aged =12?years with reported contact with COVID-19 cases, February-September 2021. Influenza Other Respir Viruses. 2022 Feb 15. doi: 10.1111/irv.12973. Online ahead of print. PubMed
Irving SA, Groom HC, Dandamudi P, Daley MF, Donahue JG, Gee J, Hechter R, Jackson LA, Klein NP, Liles E, Myers TR, Stokley S. A decade of data: adolescent vaccination in the vaccine safety datalink, 2007 through 2016. Vaccine. 2022 Feb 23;40(9):1246-1252. doi: 10.1016/j.vaccine.2022.01.051. Epub 2022 Feb 4. PubMed
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW Jr, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobrzynski D, Coler RN, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek JA, Dominguez Islas CP, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Homologous and heterologous Covid-19 booster vaccinations. N Engl J Med. 2022 Jan 26. doi: 10.1056/NEJMoa2116414. Online ahead of print. PubMed
Glanz JM, Clarke CL, Daley MF, Shoup JA, Hambidge SJ, Williams JTB, Groom HC, Kharbanda EO, Klein NP, Jackson LA, Lewin BJ, McClure DL, Xu S, DeStefano F. The childhood vaccination schedule and the lack of association with type 1 diabetes. Pediatrics. 2021 Dec 1;148(6):e2021051910. doi: 10.1542/peds.2021-051910. PubMed
Atmar RL, Lyke KE, Deming ME, Jackson LA, Branche AR, El Sahly HM, Rostad CA, Martin JM, Johnston C, Rupp RE, Mulligan MJ, Brady RC, Frenck RW, Bäcker M, Kottkamp AC, Babu TM, Rajakumar K, Edupuganti S, Dobryzynski D, Posavad CM, Archer JI, Crandon S, Nayak SU, Szydlo D, Zemanek J, Islas CPD, Brown ER, Suthar MS, McElrath MJ, McDermott AB, O'Connell SE, Montefiori DC, Eaton A, Neuzil KM, Stephens DS, Roberts PC, Beigel JH; DMID 21-0012 Study Group. Heterologous SARS-CoV-2 booster vaccinations - preliminary report. medRxiv. 2021:2021.10.10.21264827. doi: 10.1101/2021.10.10.21264827. Preprint. PubMed
El Sahly HM, Baden LR, Essink B, Doblecki-Lewis S, Martin JM, Anderson EJ, Campbell TB, Clark J, Jackson LA, Fichtenbaum CJ, Zervos M, Rankin B, Eder F, Feldman G, Kennelly C, Han-Conrad L, Levin M, Neuzil KM, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Polakowski L, Mascola JR, Ledgerwood JE, Graham BS, August A, Clouting H, Deng W, Han S, Leav B, Manzo D, Pajon R, Schödel F, Tomassini JE, Zhou H, Miller J; COVE Study Group. Efficacy of the mRNA-1273 SARS-CoV-2 vaccine at completion of blinded phase. N Engl J Med. 2021 Sep 22. doi: 10.1056/NEJMoa2113017. Online ahead of print. PubMed
Kim SS, Chung JR, Belongia EA, McLean HQ, King JP, Nowalk MP, Zimmerman RK, Balasubramani GK, Martin ET, Monto AS, Lamerato LE, Gaglani M, Smith ME, Dunnigan KM, Jackson ML, Jackson LA, Tenforde MW, Verani JR, Kobayashi M, Schrag S, Patel MM, Flannery B. mRNA vaccine effectiveness against COVID-19 among symptomatic outpatients aged =16 years in the United States, February - May 2021. J Infect Dis. 2021 Sep 8:jiab451. doi: 10.1093/infdis/jiab451. Online ahead of print. PubMed
Pegu A, O'Connell S, Schmidt SD, O'Dell S, Talana CA, Lai L, Albert J, Anderson E, Bennett H, Corbett KS, Flach B, Jackson L, Leav B, Ledgerwood JE, Luke CJ, Makowski M, Nason MC, Roberts PC, Roederer M, Rebolledo PA, Rostad CA, Rouphael NG, Shi W, Wang L, Widge AT, Yang ES; mRNA-1273 Study Group, Beigel JH, Graham BS, Mascola JR, Suthar MS, McDermott AB, Doria-Rose NA. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021 Aug 12:eabj4176. doi: 10.1126/science.abj4176. [Epub ahead of print]. PubMed
The NIH-sponsored trial will help inform decisions about vaccine approval for 12- to 17-year-olds.
The investigational vaccine is in the third phase of trials and targets flu strains expected to circulate this winter.
KPWHRI researchers analyzed data from more than 640,000 vaccine doses to understand risk of severe reactions.
Encouraging immune-response and safety data emerge from preliminary human test of genetically attenuated parasite vaccine.
Seattle NPR affiliate KUOW-FM, April 8, 2021